Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation At 12 months, mean eGFR was 51.5 mL/min/1. 73 m 2 in the imlifidase arm versus 19.3 mL/min/1. 73 m 2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1. 73 m 2 (p Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a Biologic License...

#HNSBF #HNSA Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

www.stocktitan.net/news/HNSBF/imlifidase-su...